Introduction
============

Smoking is an unquestionable risk factor for disease and consequent death because there are many toxic chemical substances in cigarette smoke (Smith and Hansch, [@b28]; Hammond and O\'Connor, [@b8]). Nicotine is the main active ingredient of tobacco and is the principal contributor that leads to smoking dependence. Because the blood levels of nicotine decrease rapidly, cotinine, a major degradation product of nicotine metabolism, is considered a specific biomarker for evaluating cigarette smoke exposure (Benowitz and Jacob, [@b4]). Its half-life is a much longer (16--20 h) than that of nicotine (2 h), is identical in biological fluids and presents higher concentrations than nicotine (Benowitz, [@b3]; Benowitz and Jacob, [@b4]). Cotinine is hydroxylated to give *trans*-3-hydroxycotinine which is eliminated predominantly as unchanged drug (Bao *et al*., [@b1]; Benowitz *et al*., [@b5]). The measurement of the ratio cotinine/*trans*-3-hydroxycotinine in smokers makes it possible to explore on a large scale the metabolism of nicotine. Such calculation is likely to facilitate links between the catabolism of nicotine and the criteria of assessment of dependency and consumption (St Helen *et al*., [@b30]; Murphy *et al*., [@b22]). However, urinary cotinine and *trans*-3-hydroxycotinine are the preferred markers because urine collection is noninvasive. Several methods are used to quantify nicotine and metabolites in human urine, including ultraperformance liquid chromatography, liquid chromatography--mass spectrometry, gas chromatography--mass spectrometry (GCMS), gas chromatography with nitrogen phosphorus detection and immunoassays (Shulgin *et al*., [@b27]; Ji *et al*., [@b13]; Meger *et al*., [@b19]; Moyer *et al*., [@b21]; Xu *et al*., [@b31]; Chao *et al*., [@b6]; Heavner *et al*., [@b9]; Kim *et al*., [@b15]; Song *et al*., [@b29]; Hoofnagle *et al*., [@b10]; Kataoka *et al*., [@b14]; Shakleya and Huestis, [@b25] and [@b26]; Baumann *et al*., [@b2]; Hu *et al*., [@b11]; Malafatti *et al*., [@b17]; Marclay and Saugy, [@b18]; Miller *et al*., [@b20]; Dobrinas *et al*., [@b7]; Jacob *et al*., [@b12]; Rangiah *et al*., [@b23]; Kuhn *et al*., [@b16]; Scheidweiler *et al*., [@b24]). Older methods include quantification of cotinine and *trans*-3-hydroxycotinine in urine by GCMS (Shulgin *et al*., [@b27]; Ji *et al*., [@b13]; Kim *et al*., [@b15]). This paper reports an automated solid-phase extraction (SPE) procedure to determine simultaneous quantification of cotinine and *trans*-3-hydroxycotinine by GCMS across a wide range of concentrations in human urine.

Experimental
============

Materials
---------

Cotinine (COT), *trans*-3-hydroxycotinine (OH-COT), cotinine-d3 and *trans*-3-hydroxycotinine-d3 were obtained from LGC Standards (Molsheim, France). Caffeine, ibuprofen, methadone, morphine, pseudoephedrine, codeine, cocaine, clomipramine, propranolol and Δ-9-tetrahydrocannabinol analytical reference standards presented in methanol were obtained from Cerilliant (Sigma-Aldrich, Saint-Quentin-Fallavier, France). Potassium dihydrogen phosphate and dipotassium hydrogen phosphate were obtained from Sigma-Aldrich (St Louis, MO, USA). Methanol, hexane, isopropanol were of analytical grade and were obtained from Merck (Darmstadt, Germany). Sterile water was obtained from Fresenius (Sevres, France). Ammonia solution 25% was purchased from VWR (Fontenay-sous-Bois, France). Hydrochloric acid 0.2 [m]{.smallcaps} was obtained from VWR (Fontenay-sous-Bois, France). Clean Screen SPE columns 200 mg were purchased from UCT (Bristol, PA, USA). The derivatizing agent utilized was *bis*(trimethylsilyl)trifluoroacetamide (BSTFA) + 1% trimethylchlorosilane (TMS) (Sigma-Aldrich, Saint-Quentin-Fallavier, France).

Blank, standard and quality controls
------------------------------------

Urine samples from nonsmoker volunteers were collected, extracted and analyzed. Urine samples with nondetectable COT and OH-COT were pooled and used in the preparation of calibration and quality control samples (QCs). The commercial solutions containing 1 mg/mL of COT and OH-COT in methanol were used as stock solutions. Three working solutions (1, 10 and 100 µg/mL) were prepared from the stock solutions. A set of eight calibrators made up of 25, 50, 100, 500, 1000, 2000, 4000 and 6000 ng/mL COT and OH-COT in urine was prepared daily from working solutions. Three QCs (30, 2500 and 5000 ng/mL) of COT and OH-COT in urine were also prepared from a separate stock solution (1 mg/mL). The internal standards, cotinine-d3 and *trans*-3-hydroxycotinine-d3, were mixed in methanol to prepare the internal standards working solution (10 µg/mL). All solutions, blank and QCs were stored at −20°C prior to analysis.

Sample preparation
------------------

An aliquot of 2 mL of urine sample, QC sample or calibration standard was mixed with 2 mL of 0.1 [m]{.smallcaps} phosphate buffer (pH 6.0). Twenty microliters of internal standards working solution were added to each sample prior to extraction. The SPE columns were preconditioned in the following order, 3 mL of methanol, 3 mL of sterile water, and 1 mL of phosphate buffer (pH 6.0). Each sample was loaded onto SPE column at 1 mL/min and washed with 3 mL of sterile water, 2 mL of 0.2 [m]{.smallcaps} hydrochloric acid, 2 mL of hexane and 3 mL of methanol. Analytes were eluted with 1 mL dichloromethane--2-propanol--concentrated ammonium hydroxide (78:20:2). This SPE protocol was entirely automated using the Gilson GX-271 ASPEC system. Extracts were evaporated to dryness under a stream of nitrogen at 35°C using a Thermec Dri-Block® DB-3D Evaporator. Residues were reconstituted in 20 μL of ethyl acetate and 20 μL of BSTFA (with 1% TMS) and derivatized at 70°C for 30 min. The derivatized extract (1 μL) was injected onto the GCMS with selected ion monitoring mode.

Gas chromatography--mass spectrometry
-------------------------------------

The Thermo Focus DSQ II gas chromatograph/mass spectrometric system was used for GC separation and detection. Helium was used as a carrier gas at a constant flow of 1.20 mL/min. The system was equipped with an Uptibond® UB5 premium column (30 m × 0.25 mm × 0.25 µm). The instrument was programmed from 70 to 190°C at 30°C/min, to 230°C at 5°C/min, and to 290°C at 25°C/min, for a total analysis time of 15 min. The transfer line temperature was maintained at 290°C. One microliter of derivatized extract was injected. The injection port temperature was held at 250°C and operated in the pulsed splitless mode. The instrument utilized electron impact ionization and was operated in the selected ion monitoring mode. The ions for each analyte were monitored in the following elution order for the derivatized analytes: cotinine-d3, *m*/*z* (122), 179; cotinine, *m*/*z* (119), 176; *trans*-3-hydroxycotinine-d3, *m*/*z* (147), 252; and *trans*-3-hydroxycotinine, *m*/*z* (249), 144.

Data analysis
-------------

Data were collected and analyzed utilizing Thermo Electron GCMS Solution software (Xcalibur™, version 1.4.2; Thermo Electron Corporation, San Jose, CA, USA).

Selectivity
-----------

Five blank urine samples from different nonsmokers were extracted and analyzed for assessment of potential interferences that may be present owing to passive smoke exposure. Potential interferences from 10 commonly used drugs were evaluated by adding compounds at concentrations of 0.2, 0.5 and 10 µg/mL (caffeine, ibuprofen, methadone, morphine, pseudoephedrine, codeine, cocaine, clomipramine, propranolol and Δ-9-tetrahydrocannabinol).

Linearity and sensitivity
-------------------------

The linearity of the method was determined by linear regression of calibrator concentrations vs peak area ratio of either COT or OH-COT peak area divided by the peak area of the respective internal standard. The linearity of the curves was accepted when each of the calibrators achieved concentration not exceeding 20% of the nominal actual concentration. The sensitivity of the assay was evaluated by determining the limit of detection (LOD) and the limit of quantification (LOQ). The LOD is the lowest concentration of an analyte determined with signal-to-noise of at least 3:1 by peak area. The LOQ is the lowest concentration of an analyte in a calibration curve and it may use the criteria of LOQ.

Precision and accuracy
----------------------

Inter- and intra-assay precision and accuracy data for COT and OH-COT were calculated by using low (50 ng/mL), medium (600 ng/mL) and high (5000 ng/mL) QC samples. Intra-assay data were assessed by comparing data from within one run (*n* = 9). Inter-assay data were determined by comparing data between six runs. Precision was expressed as percentage relative standard deviation (RSD), and accuracy was expressed as the deviation (%) of the mean concentration from nominal concentration.

Recovery
--------

Recovery was determined by adding analytes to a series of six replicates in urine with low (100 ng/mL), medium (1000 ng/mL) and high concentrations (6000 ng/mL) of each analyte that were extracted and compared nonextracted standards in methanol. Recovery was expressed as a percentage of the mean peak area of the extracted replicates divided by the mean peak area of nonextracted replicates.

Stability
---------

The stability of samples in the autosampler tray was tested using blank urine samples spiked with low (50 ng/mL), medium (600 ng/mL) and high concentrations (5000 ng/mL) of each analyte and internal standards. The spiked samples were by the procedures described above followed by evaporation, reconstitution with 20 μL ethyl acetate and 20 μL BSTFA with 1% TMS, transfer to vial insert, and placement in the autosampler tray. One microliter of the solution was injected every hour from the same sample. The response ratios of each analyte and its internal standard of successive injections were compared with that of the first injection.

Results
=======

Method validation
-----------------

A typical chromatogram for the two analytes and their internal standards can be found in Fig. [1](#fig01){ref-type="fig"}. Figure [1](#fig01){ref-type="fig"} shows that first cotinine-d3 is eluting at 7.37 min, followed by cotinine at 7.39 min, *trans*-3-hydroxycotinine-d3 at 8.87 min, and *trans*-3-hydroxicotinine at 8.89 min.

![(A) Typical chromatogram showing the elution of cotinine (COT) 100 ng/mL and *trans*-3-hydroxycotinine (OH-COT) 100 ng/mL and their respective d3-labeled internal standards (COT-D3, OH-COT-D3). (B) A chromatogram of an average smoker sample with COT 507.3 ng/mL and OH-COT 447.7 ng/mL. (C) A chromatogram of a heavy smoker with COT 3534.5 ng/mL and OH-COT 6502.5 ng/mL.](bmc0028-0453-f1){#fig01}

Linearity and sensitivity
-------------------------

Cotinine and *trans*-3-hydroxycotinine were linear over the range 10--6000 ng/mL with *R*^2^ \> 0.997 and *R*^2^ \> 0.999, respectively. The LOD and LOQ of cotinine were 0.06 and 10 ng/mL, respectively. The LOD and LOQ of *trans*-3-hydroxycotinine were 0.02 and 10 ng/mL, respectively.

Precision and accuracy
----------------------

Precision (represented by RSD) and accuracy (represented by percentage deviation) of the method results are given in Table [1](#tbl1){ref-type="table"}. Accuracy for COT ranged from 0.98 to 5.28% and the precision ranged from 1.24 to 8.78%. Accuracy for OH-COT ranged from −2.66 to 3.72% and the precision ranged from 3.15 to 7.07%.

###### 

Precision and accuracy for cotinine and *trans*-3-hydroxycotinine at three concentration levels in urine samples

                                     Intraday         Interday                                 
  --------------------------- ------ ---------------- ---------- ------ ---------------- ----- ------
  Cotinine                                                                                     
                              50     51.1 ± 1.5       2.9        2.2    52.6 ± 4.5       8.6   5.3
                              600    605.9 ± 7.5      1.2        0.9    622.4 ± 54.6     8.8   3.7
                              5000   5128.3 ± 292.5   5.8        2.6    5155.1 ± 336.6   6.5   3.1
  *Trans*-3-hydroxycotinine                                                                    
                              50     48.7 ± 1.9       4.1        -2.7   51.9 ± 1.7       3.4   3.7
                              600    618.1 ± 23.9     3.9        3.0    589.2 ± 37.5     6.4   -1.8
                              5000   5102.9 ± 160.7   3.2        2.1    5125.0 ± 362.5   7.1   2.5

Recovery
--------

Recoveries for the analytes (*n* = 6) are shown in Table [2](#tbl2){ref-type="table"}. Mean recoveries for cotinine and *trans*-3-hydroxycotinine ranged from 77.7 to 89.1%, and from 75.4 to 90.2%, respectively, for the three QC concentrations of 100, 1000 and 6000 ng/mL.

###### 

Recoveries of cotinine and *trans*-3-hydroxycotinine from urine (*n* = 6)

  Analyte                      Expected concentration (ng/mL)   Mean peak ratio of extracted samples   Mean peak ratio of nonextracted samples   Recovery (%)
  ---------------------------- -------------------------------- -------------------------------------- ----------------------------------------- --------------
  Cotinine                                                                                                                                       
                               100                              0.9                                    1.0                                       89.1
                               1000                             8.8                                    11.4                                      77.7
                               6000                             46.3                                   52.5                                      88.2
  *Trans*-3-hydroxycotinine.                                                                                                                     
                               100                              0.6                                    0.6                                       90.2
                               1000                             4.4                                    5.1                                       87.8
                               6000                             24.1                                   32.0                                      75.4

Stability
---------

Analytes concentrations in capped GC autosampler vials were stable for up to 48 h.

Discussion
==========

If some articles were published describing LC/MS methods regarding nicotine and its metabolites, only two publications described the quantification of cotinine and *trans*-3-hydroxycotinine in urine by GCMS method (Shulgin *et al*., [@b27]; Ji *et al*., [@b13]). The most recent article dated from 1999 and used liquid-liquid extraction procedure using volatile and toxic solvents as n-butyl acetate and dichloromethane (Ji *et al*., [@b13]). A recent GC method was developed for determination of urinary cotinine in active and passive smokers using liquid--liquid extraction (Malafatti *et al*., [@b17]). The sample volume of urine was high with 5.0 mL, and intra- and inter-day assay standard relative deviations were up to 14.2%. Our SPE method increased significantly the throughput and reduced the manual handling tasks associated with the liquid--liquid extraction method. However, capping SPE cartridges for use on the automated system is physically demanding and thus becomes a manual handling hazard. In Ji *et al*. ([@b13]), the inter-assay CVs were 4.2--12% for OH-COT and 10--12% for COT. In our method, inter- and intra-assay were \<9% for both analytes. This analytical method for the simultaneous measurement of cotinine and *trans*-3-hydroxycotinine in urine will be used to monitor tobacco smoking as pregnant women and will permit the usefulness of *trans*-3-hydroxycotinine as a specific biomarker of tobacco exposure to be determined.

Conclusion
==========

Our report describes a rapid, sensitive, accurate and simple method for simultaneous quantification of urinary cotinine and *trans*-3-hydroxycotinine. SPE procedure was simplified by automating the extraction of the analytes, which are the critical steps of analysis methods. The applicability of the assay should be useful for routine monitoring of active smoking and exposure to environmental tobacco smoke. *Trans*-3-hydroxycotinine requires additional data to provide a useful indicator as a biomarker for tobacco smoke and to investigate differences in the metabolism of COT and OH-COT.
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